Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Teng Long,1,2,* Zhoutian Yang,1,2,* Huilan Zeng,1,2,* Weijie Wu,1,2 Zhiwen Hu,1,2 Zhenyun Yang,1,2 Dandan Hu,1,2 Zhongguo Zhou,1,2 Minshan Chen,1,2 Yaojun Zhang1,2 1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Peopl...
Main Authors: | Long T, Yang Z, Zeng H, Wu W, Hu Z, Hu D, Zhou Z, Chen M, Zhang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-10-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/comparable-clinical-outcomes-between-transarterial-chemoembolization-o-peer-reviewed-fulltext-article-JHC |
Similar Items
-
Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
by: Yu B, et al.
Published: (2023-10-01) -
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis
by: Tengfei Si, et al.
Published: (2022-09-01) -
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01) -
High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization
by: Zhang B, et al.
Published: (2024-03-01) -
Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor
by: Lijie Zhang, et al.
Published: (2024-02-01)